Aug 12, 2020
Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck
Jun 18, 2020
Worldwide Human Papillomavirus (HPV) Vaccines Overview 2020 - Pipeline & Marketed Vaccines, Regulatory Events, Clinical Trial Landscape, Future Trends, KOL Insights, Unmet Needs, Sales (2015-2024)
Jun 18, 2020
Worldwide DNA Vaccine Market (2020 to 2022) - Increasing Focus on Genetic Vaccine Development
Jun 16, 2020
U.S. Genital Warts Market Analysis, 2017-2030 - Epidemiology, Drugs, Therapies, Vaccines, Companies, Unmet Needs, Reimbursement
Jun 09, 2020
Global Neoantigen Cancer Vaccines Market to Exhibit a CAGR of ~35% During 2020-2025
Mar 25, 2020
WHO Officials Indicating at Least 20 Vaccines in Development in Global Race for a Cure
Feb 26, 2020
Nouscom Strengthens Its Management Team
Feb 07, 2020
Disease Analysis: Human Papillomavirus (HPV) Vaccines
Jan 14, 2020
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030
Jan 14, 2020
Global Neoantigen Cancer Vaccine Market Study, 2023-2030: Projecting a CAGR of 34.69%; Generating Revenues of $227.1M in 2023 and $1.82B in 2030
Dec 18, 2019
Dendreon Signs Union City Lease Agreement
Nov 21, 2019
Elios Therapeutics Presents Primary Analysis of Phase IIb Study Showing Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients
Nov 07, 2019
Trovagene Announces Third Quarter 2019 Results and Highlights
Nov 07, 2019
Civis Analytics Kicks off "Voice of the Patient" Research Series with New Studies on Telehealth and HPV Vaccination
Sep 10, 2019
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
Aug 22, 2019
Global Cervical Cancer Vaccines Market to Surpass US$ 6 Billion by 2026
Aug 19, 2019
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
May 30, 2019
Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago
Apr 17, 2019
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress
Apr 02, 2019
With Safety Analysis Complete, Roswell Park Moves Forward With Expanded Study of CIMAvax